本文關(guān)鍵詞：STOML2蛋白在前列腺癌與前列腺增生中的差異表達(dá)及意義　出處：《華北理工大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： STOML2 前列腺癌 免疫組化 蛋白質(zhì)印跡法 Q-PCR

【摘要】：目的檢測(cè)STOML2蛋白在前列腺癌和前列腺增生組織中的表達(dá)情況,以及初步探討STOML2蛋白在前列腺癌發(fā)生發(fā)展過程中的作用。方法采用免疫組織化學(xué)方法,對(duì)收集的30例前列腺癌和30例前列腺增生患者病理切片進(jìn)行免疫組化檢測(cè),檢測(cè)STOML2蛋白的表達(dá)情況,用費(fèi)舍爾確切概率法進(jìn)行統(tǒng)計(jì)。對(duì)前列腺癌患者臨床資料進(jìn)行整理并分組,檢測(cè)每組中STOML2蛋白表達(dá)情況,并分析它們之間的相關(guān)性,用秩和檢驗(yàn)進(jìn)行統(tǒng)計(jì)。提取4例前列腺癌和4例前列腺增生術(shù)后標(biāo)本中的蛋白及總RNA,采用蛋白質(zhì)印跡法及Q-PCR實(shí)驗(yàn)方法檢測(cè)前列腺癌與前列腺增生標(biāo)本中各自的STOML2蛋白含量及m RNA含量,用獨(dú)立樣本t檢驗(yàn)進(jìn)行統(tǒng)計(jì)。結(jié)果在30例前列腺癌患者中,STOML2蛋白陽性表達(dá)24例,陰性表達(dá)6例,陽性表達(dá)率為80%(24/30);在30例前列腺增生患者中,STOML2蛋白陽性表達(dá)4例,陰性表達(dá)26例,陽性表達(dá)率為13.3%(4/30),經(jīng)統(tǒng)計(jì)學(xué)分析發(fā)現(xiàn)在前列腺癌組與前列腺增生組STOML2蛋白表達(dá)具有統(tǒng)計(jì)學(xué)意義(P0.05)。STOML2蛋白在有遠(yuǎn)處轉(zhuǎn)移組中陽性表達(dá)17例,陰性表達(dá)1例,陽性表達(dá)率為94.4%(17/18);在無遠(yuǎn)處轉(zhuǎn)移組中陽性表達(dá)7例,陰性表達(dá)5例,陽性表達(dá)率為58.3%(7/12)。經(jīng)統(tǒng)計(jì)分析發(fā)現(xiàn)在遠(yuǎn)處轉(zhuǎn)移分組中STOML2蛋白表達(dá)具有統(tǒng)計(jì)學(xué)意義(P0.05)。在前列腺患者年齡分組、術(shù)前PSA分組、前列腺體積分組、Gleason評(píng)分分組、臨床分期分組、有無淋巴結(jié)轉(zhuǎn)移分組中STOML2蛋白表達(dá)均無統(tǒng)計(jì)學(xué)意義(P0.05)。前列腺癌患者術(shù)后組織標(biāo)本中STOML2蛋白含量為(1.67±0.36);前列腺增生患者術(shù)后組織標(biāo)本中STOML2蛋白含量為(0.80±0.19)。經(jīng)統(tǒng)計(jì)學(xué)分析前列腺癌組與前列腺增生組中STOML2蛋白含量差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。前列腺癌患者術(shù)后組織標(biāo)本中STOML2基因m RNA含量為(1.97±0.67);前列腺增生患者術(shù)后組織標(biāo)本中STOML2基因m RNA含量為(0.63±0.32)。經(jīng)統(tǒng)計(jì)學(xué)分析前列腺組與前列腺增生組中STOML2基因m RNA含量差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論STOML2在前列腺癌組織中陽性表達(dá)率高于前列腺增生組織;STOML2在前列腺癌標(biāo)本中的蛋白含量及m RNA含量高于前列腺增生組織標(biāo)本。提示STOML2蛋白在前列腺癌患者中高表達(dá)及含量增加,與前列腺癌的發(fā)生關(guān)系密切。STOML2蛋白表達(dá)與前列腺癌患者有無遠(yuǎn)處轉(zhuǎn)移具有相關(guān)性,即STOML2蛋白表達(dá)與遠(yuǎn)處轉(zhuǎn)移呈正相關(guān)關(guān)系。提示隨著前列腺癌患者病情的發(fā)展,STOML2蛋白表達(dá)量升高,在前列腺發(fā)展過程發(fā)揮著重要作用。
[Abstract]:Objective to detect the expression of STOML2 protein in prostate cancer and prostatic hyperplasia. To explore the role of STOML2 protein in the development of prostate cancer. Methods Immunohistochemical method was used. The pathological sections of 30 cases of prostate cancer and 30 cases of prostatic hyperplasia were examined by immunohistochemistry to detect the expression of STOML2 protein. The clinical data of patients with prostate cancer were collected and grouped to detect the expression of STOML2 protein in each group and to analyze the correlation between them. The protein and total RNA were extracted from 4 cases of prostate cancer and 4 cases of prostatic hyperplasia by rank sum test. The contents of STOML2 protein and m RNA in prostate cancer and prostatic hyperplasia were detected by Western blot and Q-PCR. Results among 30 patients with prostate cancer, 24 cases had positive expression of STOML2 protein, 6 cases had negative expression, and the positive rate was 80% 24 / 30%. In 30 patients with benign prostatic hyperplasia (BPH), positive expression of STOML2 protein was found in 4 cases and negative expression in 26 cases. The positive rate was 13. 3% / 30). The expression of STOML2 protein in prostate cancer group and prostatic hyperplasia group was statistically significant. 17 cases with distant metastasis showed positive expression of STOML2 protein. Negative expression was found in 1 case, the positive expression rate was 94. 4% or 17 / 18; In the group without distant metastasis, 7 cases were positive and 5 cases were negative. The positive expression rate was 58.3% / 12%. Statistical analysis showed that the expression of STOML2 protein in distant metastasis group was statistically significant (P 0.05). Preoperative PSA group, prostate volume group, Gleason score group, clinical staging group. There was no significant difference in the expression of STOML2 protein in lymph node metastasis group. The content of STOML2 protein was 1.67 鹵0.36 in postoperative tissue samples of patients with prostate cancer. ; The content of STOML2 protein was 0.80 鹵0.19 in the tissue of patients with prostatic hyperplasia after operation. The difference of STOML2 protein content between prostate cancer group and prostatic hyperplasia group was statistically significant (P 0.05). The content of m RNA of STOML2 gene was 1.97 鹵0.67 in the tissue of patients with prostate cancer after operation. The content of STOML2 gene m RNA was 0.63 鹵0.32 in postoperative tissue samples of patients with benign prostatic hyperplasia (BPH). The difference of m RNA content of STOML2 gene between prostatic group and prostatic hyperplasia group was statistically significant (P0.05). Conclusion the positive expression rate of STOML2 in prostate cancer is higher than that in prostatic hyperplasia. The protein content and m RNA content of STOML2 in prostate cancer samples were higher than those in benign prostatic hyperplasia tissues, suggesting that the expression and content of STOML2 protein were increased in prostate cancer patients. The expression of STOML2 protein is closely related to the occurrence of prostate cancer. There is a correlation between the expression of STOML2 protein and the distant metastasis of prostate cancer patients. That is, the expression of STOML2 protein is positively correlated with distant metastasis, which suggests that the expression of STOML2 protein increases with the development of prostate cancer, and plays an important role in the development of prostate cancer.
【學(xué)位授予單位】：華北理工大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R737.25;R697.3
，

本文編號(hào)：1400604